March 2022

26 Mar Rucaparib significantly prolongs PFS compared with chemotherapy in women with BRCA-mutated advanced, relapsed ovarian cancer, who received 3 or more lines of prior therapies

In patients with relapsed, BRCA1-mutated or BRCA2-mutated ovarian cancer, who received 2 or more lines of prior therapies, Rucaparib showed significantly longer median progression-free survival of 7.4 months compared to 5.7 months with chemotherapy (platinum-based and non-platinum-based chemotherapy). # ARIEL4 study. (Ref: Kristeleit R et al. The lancet Oncology March 14, 2022)
#oncologyresearch

https://www.linkedin.com/feed/update/urn:li:activity:6913402413664104448

19 Mar Ribociclib Plus Letrozole Extends Survival in Patients with Metastatic Breast Cancer

Ribociclib plus letrozole showed a significant overall survival benefit as compared with placebo plus letrozole. Median overall survival was 63.9 months (95% CI, 52.4 to 71.0) with ribociclib plus letrozole and 51.4 months (95% CI, 47.2 to 59.7) with placebo plus letrozole (HR for death, 0.76; 95% CI, 0.63 to 0.93; P=0.008).

Front line therapy with the combo improved median overall survival by 1 year compared to letrozole alone.
(Ref: Hortobagyi et al.NEJM March 10, 2022.)

https://www.linkedin.com/feed/update/urn:li:activity:6910855914283540480

11 Mar Mechanisms of resistance to noncovalent Bruton Tyrosine Kinase inhibitors is delineated

The mechanisms of resistance to noncovalent (reversible) BTK inhibitors was not fully known. Genomic analyses of pre and post-treatment samples from patients with CLL treated with the non-covalent BTK inhibitor pirtobrutinib showed that resistance to noncovalent BTK inhibitors arose through on-target BTK mutations and downstream PLCγ2 mutations. This data suggests new mechanisms of genomic escape from established covalent and novel noncovalent BTK inhibitors. (Ref: Wang E et al.NEJM, 2022)

https://www.linkedin.com/feed/update/urn:li:activity:6907962121779597312